Based on the experimental evidence reported above, we started to evaluate the effects of MR antagonism in FPLD2 patients undergoing spironolactone therapy to counteract hyperandrogenism and other metabolic abnormalities. The gene discussed is NR3C2; the disease is hyperandrogenism.